# Kyle Gano

> Kyle W. Gano is the San Diego-based CEO and a director of Neurocrine Biosciences. He joined in 2001 as a summer intern, moved through marketing analytics and business development, became Chief Business Development Officer in 2011, added strategy to his title in 2020, and succeeded Kevin Gorman on October 11, 2024. His education spans chemistry, biochemistry, organic chemistry and business administration.

- **Role:** Chief Executive Officer at Neurocrine Biosciences
- **Organizations:** Neurocrine Biosciences, Pharmaceutical Research and Manufacturers of America (PhRMA)
- **Education:** B.S. in Chemistry, University of Oregon, B.S. in Biochemistry, University of Washington, Ph.D. in Organic Chemistry, University of California, Los Angeles, M.B.A. in Finance, UCLA Anderson School of Management
- **Known for:** Advanced from summer intern to CEO within Neurocrine over 23 years., Executed and managed strategic partnerships including AbbVie, Mitsubishi Tanabe Pharma, Takeda, Voyager Therapeutics and Xenon Pharmaceuticals., Serves on the boards of Neurocrine Biosciences and PhRMA.

## Career timeline

- **2000** — Listed as a presenter at UCLA’s Organic Chemistry Graduate Symposium, with a talk titled User-Defined Patterning at the Molecular Scale.
- **2001** — Joined Neurocrine as a summer intern between the first and second years of business school.
- **2001–2011** — Held roles spanning marketing analytics and business development at Neurocrine.
- **2011** — Appointed Chief Business Development Officer.
- **2020** — Appointed Chief Business Development and Strategy Officer.
- **2024-05** — Named CEO-elect in Neurocrine’s succession announcement.
- **2024-10-11** — Became President and CEO and joined Neurocrine’s board, succeeding Kevin Gorman.

## Achievements

- Advanced from summer intern to CEO within Neurocrine over 23 years.
- Executed and managed strategic partnerships including AbbVie, Mitsubishi Tanabe Pharma, Takeda, Voyager Therapeutics and Xenon Pharmaceuticals.
- Serves on the boards of Neurocrine Biosciences and PhRMA.

## Latest updates

- **2026-07** — Signed Neurocrine’s CEO certification for its quarterly report for the period ended June 30, 2026, dated July 30, 2026.
- **2026-05** — Neurocrine completed its acquisition of Soleno Therapeutics on May 18, 2026, during Gano’s tenure as CEO.
- **2026-01** — Appeared in a BiotechTV interview published January 15, 2026.

## Links

- Website: https://www.neurocrine.com/leadership/kyle-w-gano-phd/
- LinkedIn: https://www.linkedin.com/in/kylegano

---

Profile page: https://yespress.io/kyle-gano
Published by YesPress — https://yespress.io
Last updated: 2026-10-23